title: Neuropathological changes in the substantia nigra in schizophrenia but not depression.
abstract: Schizophrenia is a chronic, disabling neuropsychiatric disorder characterised by positive, negative and cognitive symptoms. The aetiology is not known, although genetic, imaging and pathological studies have implicated both neurodevelopmental and neurodegenerative processes. The substantia nigra is a basal ganglia nucleus responsible for the production of dopamine and projection of dopaminergic neurons to the striatum. The substantia nigra is implicated in schizophrenia as dopamine has been heavily implicated in the dopamine hypothesis of schizophrenia and the prevalent psychotic symptoms and the monoamine theory of depression, and is a target for the development of new therapies. Studies into the major dopamine delivery pathways in the brain will therefore provide a strong base in improving knowledge of these psychiatric disorders. This post-mortem study examines the cytoarchitecture of dopaminergic neurons of the substantia nigra in schizophrenia (n = 12) and depression (n = 13) compared to matched controls (n = 13). Measures of nucleolar volume, nuclear length and nuclear area were taken in patients with chronic schizophrenia and major depressive disorder against matched controls. Astrocyte density was decreased in schizophrenia compared to controls (p = 0.030), with no change in oligodendrocyte density observed. Significantly increased nuclear cross-sectional area (p = 0.017) and length (p = 0.021), and increased nucleolar volume (p = 0.037) in dopaminergic neurons were observed in schizophrenia patients compared with controls, suggesting nuclear pleomorphic changes. No changes were observed in depression cases compared to control group. These changes may reflect pathological alterations in gene expression, neuronal structure and function in schizophrenia.
authors.affiliation: Institute of Psychiatry, King's College London, De Crespigny Park, London, SE5 8AF, UK, matthew.r.williams@imperial.ac.uk.
authors.forename: M R
authors.initials: MR
authors.lastname: Williams
authors.forename: K
authors.initials: K
authors.lastname: Galvin
authors.forename: B
authors.initials: B
authors.lastname: O'Sullivan
authors.forename: C D
authors.initials: CD
authors.lastname: MacDonald
authors.forename: E W K
authors.initials: EW
authors.lastname: Ching
authors.forename: F
authors.initials: F
authors.lastname: Turkheimer
authors.forename: O D
authors.initials: OD
authors.lastname: Howes
authors.forename: R K B
authors.initials: RK
authors.lastname: Pearce
authors.forename: S R
authors.initials: SR
authors.lastname: Hirsch
authors.forename: M
authors.initials: M
authors.lastname: Maier
mesh_terms: D000328:Adult; D000368:Aged; D003863:Depression / Q000473:pathology*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009474:Neurons / Q000473:pathology; D011180:Postmortem Changes; D012559:Schizophrenia / Q000473:pathology*; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology*
chemical_list: D005904:Glial Fibrillary Acidic Protein